BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...
BioCentury | Jan 4, 2019
Clinical News

Sunovion's SEP-363856 meets in Phase II for schizophrenia

...Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in the...
...is in January 2020. Sunovion is a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506). PsychoGenics Inc....
...NA SEP-363856 is an antipsychotic targeting serotonin (5-HT1A) receptor and trace amine-associated receptor 1 (TAAR1). Brian Moy SEP-363856 PsychoGenics Inc. Sumitomo...
BioCentury | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-201 started

...have the right to pursue an IND submission for compounds evaluated with PsychoGenics’ SmartCube platform. PsychoGenics...
...SmartCube platform. PsychoGenics said Sunovion chose to move forward with the development of SEP-363856, while PsychoGenics...
...development of the compound and is eligible for royalties (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....
BioCentury | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-203 started

...product was discovered under a 2007 deal with PsychoGenics (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....
...Neuropsychiatric Inventory (NPI), Mini-Mental State Exam (MMSE) and safety Status: Phase II started Milestone: NA Chris Lieu SEP-363856 PsychoGenics Inc. Sumitomo...
BioCentury | Jun 29, 2016
Financial News

Intensity raises $10M in series A

...and head and neck cancers. Doogan, a partner at Mediqventures, and Emer Leahy, CEO of PsychoGenics Inc....
BioCentury | Feb 8, 2016
Company News

UCSD, PsychoGenics deal

...The university granted PsychoGenics a license to a mouse model expressing human amyloid precursor protein (APP...
...plaque deposition in the cerebral cortex and hippocampus as early as three to four months. PsychoGenics...
...early Alzheimer’s disease-associated phenotypes. The university declined to provide further details or financial terms, and PsychoGenics...
BioCentury | Jan 4, 2016
Clinical News

Eltoprazine: Clinical trial data

...from PsychoGenics (see BioCentury, Jan. 20, 2014). Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....
BioCentury | Oct 12, 2015
Company News

PsychoGenics, Sumitomo Dainippon deal

...Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary and PsychoGenics extended for four years an August 2007 deal...
...one compound into clinical testing under the deal. The companies did not respond to inquiries. PsychoGenics Inc....
BioCentury | Oct 12, 2015
Clinical News

Eltoprazine: Phase IIb halted

...enrollment next year. Amarantus has exclusive, worldwide rights, excluding countries in Asia, to eltoprazine from PsychoGenics...
...Phase II testing for intractable severe burns. Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....
BioCentury | Sep 28, 2015
Company News

UCSD, PsychoGenics deal

...The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse...
...partners did not respond to inquiries. University of California San Diego , La Jolla, Calif. PsychoGenics Inc....
Items per page:
1 - 10 of 59
BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

Harvard physician scientist Michael Fox is using brain imaging to map neurological symptoms to the circuits that drive them, and thinks his connectivity maps can yield opportunities for drug developers. Fox, an associate professor of...
BioCentury | Jan 4, 2019
Clinical News

Sunovion's SEP-363856 meets in Phase II for schizophrenia

...Sunovion Pharmaceuticals Inc. and partner PsychoGenics Inc. (Paramus, N.J.) said SEP-363856 met the primary endpoint in the...
...is in January 2020. Sunovion is a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506). PsychoGenics Inc....
...NA SEP-363856 is an antipsychotic targeting serotonin (5-HT1A) receptor and trace amine-associated receptor 1 (TAAR1). Brian Moy SEP-363856 PsychoGenics Inc. Sumitomo...
BioCentury | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-201 started

...have the right to pursue an IND submission for compounds evaluated with PsychoGenics’ SmartCube platform. PsychoGenics...
...SmartCube platform. PsychoGenics said Sunovion chose to move forward with the development of SEP-363856, while PsychoGenics...
...development of the compound and is eligible for royalties (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....
BioCentury | Dec 13, 2016
Clinical News

SEP-363856: Ph II SEP361-203 started

...product was discovered under a 2007 deal with PsychoGenics (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc....
...Neuropsychiatric Inventory (NPI), Mini-Mental State Exam (MMSE) and safety Status: Phase II started Milestone: NA Chris Lieu SEP-363856 PsychoGenics Inc. Sumitomo...
BioCentury | Jun 29, 2016
Financial News

Intensity raises $10M in series A

...and head and neck cancers. Doogan, a partner at Mediqventures, and Emer Leahy, CEO of PsychoGenics Inc....
BioCentury | Feb 8, 2016
Company News

UCSD, PsychoGenics deal

...The university granted PsychoGenics a license to a mouse model expressing human amyloid precursor protein (APP...
...plaque deposition in the cerebral cortex and hippocampus as early as three to four months. PsychoGenics...
...early Alzheimer’s disease-associated phenotypes. The university declined to provide further details or financial terms, and PsychoGenics...
BioCentury | Jan 4, 2016
Clinical News

Eltoprazine: Clinical trial data

...from PsychoGenics (see BioCentury, Jan. 20, 2014). Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....
BioCentury | Oct 12, 2015
Company News

PsychoGenics, Sumitomo Dainippon deal

...Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary and PsychoGenics extended for four years an August 2007 deal...
...one compound into clinical testing under the deal. The companies did not respond to inquiries. PsychoGenics Inc....
BioCentury | Oct 12, 2015
Clinical News

Eltoprazine: Phase IIb halted

...enrollment next year. Amarantus has exclusive, worldwide rights, excluding countries in Asia, to eltoprazine from PsychoGenics...
...Phase II testing for intractable severe burns. Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. PsychoGenics Inc....
BioCentury | Sep 28, 2015
Company News

UCSD, PsychoGenics deal

...The university’s school of medicine granted PsychoGenics worldwide rights to an alpha synuclein (SNCA) transgenic mouse...
...partners did not respond to inquiries. University of California San Diego , La Jolla, Calif. PsychoGenics Inc....
Items per page:
1 - 10 of 59